Karyopharm Therapeutics Inc

This study tests whether adding the drug selinexor to standard chemotherapy (R-GDP) helps people with relapsed or refractory diffuse large B-cell lymphoma (a type of blood cancer) who cannot have a stem cell transplant or CAR-T therapy. About 500 participants will receive either …

This study tests a drug called selinexor combined with other standard treatments for multiple myeloma, a type of blood cancer. It includes 300 patients whose cancer has come back or is hard to treat, as well as some newly diagnosed patients. The goal is to find the best doses and…

This study was designed to test the safety and effectiveness of combining the drug selinexor with other treatments for people whose diffuse large B-cell lymphoma had come back or stopped responding to therapy. It planned to enroll adults with this type of lymphoma who had already…

This study tests a drug called selinexor in people with myelofibrosis, a rare bone marrow disorder, whose disease has not improved enough after at least 6 months of standard JAK inhibitor therapy. About 112 participants will be randomly assigned to receive either selinexor or ano…

This study tests an experimental drug called selinexor in adults with relapsed or refractory diffuse large B-cell lymphoma (a type of blood cancer) who have run out of standard treatments. The main goal is to see how many patients respond to the drug. About 244 participants will …

This study tests whether adding the drug selinexor to the standard treatment ruxolitinib works better than ruxolitinib alone for people with myelofibrosis, a rare bone marrow cancer. About 353 adults with moderate-to-high risk disease who have not had prior treatment will take pa…